SI

SillaJen, Inc.

Biotechnology company developing oncolytic viral therapies for cancer treatment.

215600 | KO

Overview

Corporate Details

ISIN(s):
KR7215600008
LEI:
Country:
South Korea
Address:
서울특별시 중구 청계천로 106 3층(수표동, 크리스탈스퀘어), 중구

Description

SillaJen, Inc. is a biotechnology company focused on the research and development of oncolytic immunotherapeutics for cancer treatment. The company engineers genetically modified viruses designed to selectively target and destroy cancer cells while stimulating a systemic anti-tumor immune response. Its lead product candidate is Pexa-Vec (JX-594), an oncolytic vaccinia virus developed for the treatment of various solid tumors. SillaJen's core activity involves advancing its pipeline of novel cancer-fighting viral therapies through clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-10-24 00:00
전환사채(해외전환사채포함)발행후만기전사채취득(제33회차)
Korean 12.3 KB
2023-09-14 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 56.2 KB
2023-09-14 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 33.1 KB
2023-09-12 00:00
[기재정정]투자판단관련주요경영사항(진행성 고형암 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법과의 병용요법에 대한 제1상 임상시험 …
Korean 17.8 KB
2023-08-24 00:00
[기재정정]반기보고서 (2023.06)
Korean 1.3 MB
2023-08-14 00:00
반기보고서 (2023.06)
Korean 1.3 MB
2023-07-24 00:00
전환사채(해외전환사채포함)발행후만기전사채취득(제33회차)
Korean 11.9 KB
2023-06-29 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 21.8 KB
2023-05-15 00:00
분기보고서 (2023.03)
Korean 1.0 MB
2023-04-24 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.4 KB
2023-04-13 00:00
투자판단관련주요경영사항(진행성 고형암 환자를 대상으로 BAL0891의 단일요법 및 항암화학요법과의 병용요법에 대한 제1상 임상시험 계획(IND…
Korean 12.5 KB
2023-04-11 00:00
불성실공시법인미지정
Korean 5.1 KB
2023-03-31 00:00
정기주주총회결과
Korean 19.0 KB
2023-03-23 00:00
감사보고서제출
Korean 25.7 KB
2023-03-23 00:00
사업보고서 (2022.12)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all SillaJen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SillaJen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SillaJen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.